DIRS.INFO The most relevant business & tech news

☆ Stifel says this under-the-radar biotech stock can still rally more than 50% from here
▼ + stars: | 2023-11-02 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +1 min

It's not too late for investors to ride along with MoonLake Immunotherapeutics despite the Swiss biotech having more than quadrupled in price this year, according to Stifel. Shares of MoonLake have soared 354% in 2023, but Stifel believes more gains lay ahead. MLTX YTD mountain MLTX YTD chart Analyst Alex Thompson believes MoonLake's sonelokimab drug, which targets diseases in dermatology and rheumatology, could eventually achieve $4.2 billion in U.S. revenue. The next trial readout for the drug is in psoriatic arthritis, with data expected in early November. "We view recent acquisitions in the TYK2 and TL1A space ($4-11B) as supportive of Strategics' interest/willingness to pay premiums in these markets," Stifel noted.

Persons: It's, MoonLake Immunotherapeutics, Stifel, Alex Thompson, we've, Thompson, MoonLake, — CNBC's Michael Bloom

☆ Wells Fargo says this biopharmaceutical stock could double due to drug catalysts
▼ + stars: | 2023-03-21 | by ( Alex Harring | ) www.cnbc.com time to read: +1 min

Catalysts coming for Ventyx 's immunology and inflammation projects could help the stock more than double its share value, Wells Fargo said. Analyst Derek Archila initiated coverage of the biopharmaceutical stock at overweight and set a target price for the stock at $77. His price target implies the stock will surge 103.4% over the next year from where it closed Monday. But Archila said there's a likely chance that the company could set a new bar with its trial for moderately to severely active ulcerative colitis. Wall Street expectations for the read-out coming in the second half of this year would be "highly impressive" if met, Archila said.

☆ Goldman Sachs says this little-known biotech stock can jump more than 50%
▼ + stars: | 2022-12-19 | by ( Sarah Min | ) www.cnbc.com time to read: +1 min

Shares of Ventyx Biosciences could surge more than 50% on a competitive slate of treatments for autoimmune diseases, according to Goldman Sachs. Analyst Chris Shibutani initiated coverage of Ventyx Biosciences with a buy rating, saying the company has a promising new oral treatment in development for plaque psoriasis. The TYK2 inhibitor from Ventyx Biosciences is notable, because it's expected to have "one of the cleanest safety profiles" among its competitors. "Commercially, VTX958 is being developed for large, well-established I & I markets that generate tens of billions of dollars in annual sales," Shibutani wrote. Shares of Ventyx Biosciences have surged more than 60% in 2022.

☆ Au fost identificate gene asociate unor forme grave de COVID-19
▼ + stars: | 2020-12-12 | by ( ) www.jurnal.md time to read: +1 min

Studiul sugerează că formele grave de COVID-19 au la bază cel puţin două mecanisme biologice: tipul apărării antivirale înnăscute - importantă în primele faze ale bolii - şi procesele inflamatorii dezvoltate de bolnav. Echipa care a realizat cercetarea consideră că testele clinice trebuie axate pe medicamentele care vizează aceste căi antivirale şi antiinflamatorii specifice. Diferenţe au fost descoperite în genele IFNAR2, TYK2, OAS1, DPP9 şi CCR2, ceea ce explică, în parte, de ce unele persoane dezvoltă forme grave de COVID-19, în timp ce altele nu sunt afectate, notează această universitate. S-a observat astfel că o diminuare a activităţii genei TYK2 protejează împotriva infectării cu SARS-CoV-2 şi că medicamente antiinflamatoare din categoria inhibitoarelor JAK produc acest efect. Acelaşi studiu mai semnalează că o creştere a activităţii genei INFAR2 creează ''probabil'' protecţie în faţa noului coronavirus, întrucât ar putea imita efectul tratamentului cu interferon.

Persons: Kenneth Baillie Organizations: Universitatea din Locations: Universitatea din Edinburgh, Diferenţe, TYK2, OAS1

Search resuls for: "TYK2"

4 mentions found